Efficacy and safety of thermal ablation for large hepatic caudate lobe hemangioma

Table 1 Perioperative data of patients and hemangiomas

Patient ID	Age/sex	Tumor size (cm)	Location	Reasons for therapy	Treatment method	Operative time (minute)	Intraoperative blood loss (mL)	Postoperative hospital stay (days)	Radiological response	Clinical response	Hospital cost (RMB)
1	33/F	6.4	Paracaval portion	Enlargement of hemangioma	LMWA	130	20	5	Yes	/	29242
2	52/M	10.8	Paracaval portion	Symptom and enlargement of hemangioma	LMWA	150	10	3	Yes	Symptoms present but improved	27018
3	57/F	8.4	Spiegel lobe	Enlargement of hemangioma	LIRC	105	40	1	Yes	/	33427
4	33/F	6.7	Spiegel lobe	Enlargement of hemangioma	LMWA	180	50	4	Yes	/	30562
5	33/F	6.0	Spiegel lobe	Symptom related to hemangioma	LMWA	40	10	2	Yes	Disappearance of symptoms	35548
6	54/F	11.0	Spiegel lobe	Enlargement of hemangioma	LMWA	165	20	6	Yes	/	29003
7	42/M	12.0	Paracaval portion	Symptom and enlargement of hemangioma	LMWA	130	30	2	Yes	Disappearance of symptoms	28794
8	29/M	7.0	Spiegel lobe	Enlargement of hemangioma	LIRC	120	45	3	Yes	/	35980
9	55/M	6.5	Paracaval portion	Symptom and enlargement of hemangioma	CT-RFA	30	0	2	Yes	Disappearance of symptoms	36125
10	66/M	7.0	Caudate process	Symptom and enlargement of hemangioma	CT-RFA	20	0	4	Yes	Disappearance of symptoms	26643
11	29/M	6.7	Paracaval portion	Enlargement of hemangioma	CT-RFA	30	0	2	Yes	/	29650
12	53/M	9.8	Paracaval portion	Enlargement of hemangioma	LMWA	80	10	5	Yes	/	29406
13	36/F	6.7	Caudate process	Enlargement of hemangioma	CT-RFA	30	0	1	Yes	/	27964
14	28/F	7.0	Caudate process	Enlargement of hemangioma	CT-RFA	25	0	1	Yes	/	36329
15	31/F	6.0	Spiegel lobe	Enlargement of hemangioma	LMWA	165	15	2	Yes	/	27076
16	32/F	9.6	Paracaval portion	Enlargement of hemangioma	LMWA	130	10	3	Yes	/	23723

F: Female; M: Male; LMWA: Laparoscopic microwave ablation; LIRC: Laparoscopic intratumoral resection facilitated by coagulation; CT-RFA: Computed tomography-guided radiofrequency ablation.

Table 2 Changes in the maximal diameter of the lesions after treatment at each follow-up, mean ± SD/median (interquartile range)

	Diameter	DRR	P value
Baseline	7.0 (6.7-9.6)
1 month	5.0 ± 2.6	2.3 (2.0-2.8)	< 0.001
6 months	3.6 ± 2.1	3.9 (3.6-4.8)	< 0.001
12 months	1.0 (0.0-1.8)	6.8 ± 1.1	< 0.001

DRR: Diameter reduction ratio.